Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis
To the Editor, The use of drug-eluting balloons (DEB) represents a novel and growing alternative therapeutic strategy for patients with in-stent restenosis (ISR).1 A recent publication in REC: Interventional Cardiology presented the real-world safety and efficacy data on the use of the Essential Pro...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2025-05-01
|
| Series: | REC: Interventional Cardiology (English Ed.) |
| Online Access: | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=2656 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032936251817984 |
|---|---|
| author | Lucio Padilla Jorge Tello Pablo Lamelas |
| author_facet | Lucio Padilla Jorge Tello Pablo Lamelas |
| author_sort | Lucio Padilla |
| collection | DOAJ |
| description | To the Editor, The use of drug-eluting balloons (DEB) represents a novel and growing alternative therapeutic strategy for patients with in-stent restenosis (ISR).1 A recent publication in REC: Interventional Cardiology presented the real-world safety and efficacy data on the use of the Essential Pro (iVascular, Spain) DEB in patients with ISR.2 A potential limitation of such analysis is that overall outcome event rates may be influenced by those treated more recently with short-term follow-up. These patients might not have been followed long enough to see whether they developed adverse events, thus systematically underestimating the adverse event rates. Therefore, we present the updated follow-up of that cohort reporting the results of patients, at least, 1 year from DEB use, both at the 1-year and total follow-up after DEB use (table 1). Table 1. Updated 1-year and overall follow-up n = 150 Death MI TLR LT MACE 1-year, % (n) 1.3 (2) 2.0 (3) 3.3 (5) 0 (0) 6.0 (9) All follow-up, % (n) 1.3 (2) 2.0 (3) 12.9 (10) 0 (0) 17.7 (14) The 1-year rate are crude estimates, all follow-up analysis are presented as per Kaplan-Meier analysis. LT, lesion thrombosis; MACE, major adverse cardiovascular events; MI, myocardial infarction; TLR, target lesion revascularization. The original study was approved by the local institutional review board. Furthermore, patients gave their prior... |
| format | Article |
| id | doaj-art-592f7128d30b440588cdcddd2dc6ca30 |
| institution | DOAJ |
| issn | 2604-7322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Permanyer |
| record_format | Article |
| series | REC: Interventional Cardiology (English Ed.) |
| spelling | doaj-art-592f7128d30b440588cdcddd2dc6ca302025-08-20T02:58:26ZengPermanyerREC: Interventional Cardiology (English Ed.)2604-73222025-05-017213013110.24875/RECICE.M25000502Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosisLucio Padilla0Jorge Tello1Pablo Lamelas2Servicio de Cardiología Intervencionista, Instituto Cardiovascular de Buenos Aires, Buenos Aires, ArgentinaServicio de Cardiología Intervencionista, Instituto Cardiovascular de Buenos Aires, Buenos Aires, ArgentinaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. Servicio de Cardiología Intervencionista, Fundación Favaloro, Buenos Aires, ArgentinaTo the Editor, The use of drug-eluting balloons (DEB) represents a novel and growing alternative therapeutic strategy for patients with in-stent restenosis (ISR).1 A recent publication in REC: Interventional Cardiology presented the real-world safety and efficacy data on the use of the Essential Pro (iVascular, Spain) DEB in patients with ISR.2 A potential limitation of such analysis is that overall outcome event rates may be influenced by those treated more recently with short-term follow-up. These patients might not have been followed long enough to see whether they developed adverse events, thus systematically underestimating the adverse event rates. Therefore, we present the updated follow-up of that cohort reporting the results of patients, at least, 1 year from DEB use, both at the 1-year and total follow-up after DEB use (table 1). Table 1. Updated 1-year and overall follow-up n = 150 Death MI TLR LT MACE 1-year, % (n) 1.3 (2) 2.0 (3) 3.3 (5) 0 (0) 6.0 (9) All follow-up, % (n) 1.3 (2) 2.0 (3) 12.9 (10) 0 (0) 17.7 (14) The 1-year rate are crude estimates, all follow-up analysis are presented as per Kaplan-Meier analysis. LT, lesion thrombosis; MACE, major adverse cardiovascular events; MI, myocardial infarction; TLR, target lesion revascularization. The original study was approved by the local institutional review board. Furthermore, patients gave their prior...https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=2656 |
| spellingShingle | Lucio Padilla Jorge Tello Pablo Lamelas Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis REC: Interventional Cardiology (English Ed.) |
| title | Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis |
| title_full | Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis |
| title_fullStr | Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis |
| title_full_unstemmed | Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis |
| title_short | Extended follow-up of the Essential Pro paclitaxel drug-eluting balloon for in-stent restenosis |
| title_sort | extended follow up of the essential pro paclitaxel drug eluting balloon for in stent restenosis |
| url | https://recintervcardiol.org/en/index.php?option=com_content&view=article&id=2656 |
| work_keys_str_mv | AT luciopadilla extendedfollowupoftheessentialpropaclitaxeldrugelutingballoonforinstentrestenosis AT jorgetello extendedfollowupoftheessentialpropaclitaxeldrugelutingballoonforinstentrestenosis AT pablolamelas extendedfollowupoftheessentialpropaclitaxeldrugelutingballoonforinstentrestenosis |